The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Viral Vectors (VV) based ATMP Therapies have been in commercial manufacturing for over 10 years. The science of VV-based ATMPs continues to evolve rapidly. This has had a marked impact to the design of ATMP manufacturing facilities. This presentation reviews three case studies which demonstrate the evolution of facilities designed and built in the past 5 years. The presentation will showcase how facility design innovation has evolved as the therapies and their manufacturing has become more complicated.
